Sidney Xi Liang

This inventor holds 15 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Eli Lilly and Company, Bayer Pharmaceuticals Corporation, Bayer Healthcare LLC. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sidney Xi Liang. Retrieved from https://idiyas.com/inventor/sidney-xi-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 46.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 5.7

ph-index = 4

Forward Citations = 46(Granted Patents)

Location History:

Hamden, CT (US) (2003 - 2004)
Fishers, IN (US) (1998 - 2006)
Bethany, CT (US) (2005 - 2020)

Company Filing History:

7 out of 4,517

Eli Lilly and Company

patents

5 out of 71

Bayer Pharmaceuticals Corporation

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

JAK 1 Inhibitors

Amino Compounds

Pyrrolo Derivatives

Indane Acetic Acid

Pharmaceutical Agents

Anilinopyrazole

Naphthyridine Derivatives

Serotonin Agonists

Piperidine

Diabetes Treatment

5-HT(2c) Agonists

Reuptake Inhibitors

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492204 - Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors (2025-12-09),

2. 10703756 - Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof (2020-07-07),

3. 8748459 - [object Object] (2014-06-10),

4. 7906653 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2011-03-15),

5. 7714004 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2010-05-11),

6. 7476742 - Indane acetic acid derivatives and their use as pharmaceutical agents (2009-01-13),

7. 7423050 - [object Object] (2008-09-09),

8. 7265144 - Anilinopyrazole derivatives useful for the treatment of diabetes (2007-09-04),

9. 7109196 - 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders (2006-09-19),

10. 7045545 - Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists (2006-05-16),

11. 6900205 - 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders (2005-05-31),

12. 6828332 - Piperidine derivatives as reuptake inhibitors (2004-12-07),

13. 6664274 - Piperidine derivatives as serotonine reuptake inhibitors (2003-12-16),

14. 6436964 - Piperidine derivatives having effects on serotonin related systems (2002-08-20),

15. 5792763 - Serotonin 5-HT.sub.1F agonists (1998-08-11),

Title: Sidney Xi Liang: Innovator in Pharmaceutical Chemistry

Introduction

Sidney Xi Liang is a prominent inventor based in Bethany, CT (US), known for his significant contributions to pharmaceutical chemistry. With a total of 14 patents to his name, Liang has made remarkable advancements in the field, particularly in the development of compounds that target specific biological pathways.

Latest Patents

Liang's latest patents include innovative compounds such as pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, and pyrrolo[2,3-B]pyridinyl acrylamides and epoxides. These compounds are designed to be pharmaceutically active and are particularly useful for inhibiting Janus Kinase (JAK). Additionally, he has developed compounds that activate 5-HT receptors, which are beneficial for treating and preventing migraines in mammals. His inventions also encompass methods for synthesizing these compounds and their intermediates.

Career Highlights

Throughout his career, Sidney Xi Liang has worked with leading pharmaceutical companies, including Eli Lilly and Company and Bayer Pharmaceuticals Corporation. His work has significantly impacted the development of new therapeutic agents, showcasing his expertise in medicinal chemistry.

Collaborations

Liang has collaborated with notable colleagues in the field, including Yao-Chang Xu and Daniel Timothy Kohlman. These partnerships have fostered innovation and contributed to the advancement of pharmaceutical research.

Conclusion

Sidney Xi Liang's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to influence the development of new treatments for various medical conditions.

Profile summary based on public USPTO records.